Information Provided By: 
Fly News Breaks for June 10, 2015
JAZZ
Jun 10, 2015 | 06:48 EDT
After surveying physicians who treat narcolepsy and obstructive sleep apnea patients with excessive daytime sleepiness, Piper Jaffray sees a "strong" appetite for new stimulant treatment options. The firm believes Jazz Pharmaceuticals' JZP-110 is well-positioned to gain "significant traction," assuming the Phase III data is positive. The firm thinks peak sales of JZP-110 could reach $500M. It finds shares of Jazz attractively valued and reiterates an Overweight rating on the stock with a $208 price target.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
